2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Novo Nordisk asserts its acquisition of Metsera won't pose antitrust problems as it competes with Pfizer for dominance in the ...

Phio Pharmaceuticals shares were higher after the company reported positive pathology results for its Phase 1b Intasyl PH-762 trial. The stock was 32% higher, at $2.72. Shares are up 55% year to date.

Terns Pharmaceuticals shares jumped after the company shared positive data for its leukemia treatment TERN-701. The stock gained 83% to $15.09 on Monday, putting it on track for its highest close ...

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

Key Points Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund ...

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: ...

Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the ...

The Food and Drug Administration’s top drug regulator has resigned after being accused of soliciting a bribe and tanking a ...